Replimune Group (NASDAQ:REPL) Stock Price Up 7.2% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) was up 7.2% during mid-day trading on Thursday . The stock traded as high as $8.15 and last traded at $8.1590. Approximately 186,713 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 1,416,083 shares. The stock had previously closed at $7.61.

Analysts Set New Price Targets

A number of equities analysts have recently commented on REPL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Wedbush increased their price objective on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Finally, Piper Sandler raised their target price on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

Replimune Group Stock Performance

The company has a 50-day moving average price of $7.57 and a two-hundred day moving average price of $7.80. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $645.23 million, a P/E ratio of -2.27 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after buying an additional 6,653 shares in the last quarter. Millennium Management LLC lifted its position in shares of Replimune Group by 2.8% during the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after acquiring an additional 33,574 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares during the period. Rhumbline Advisers boosted its stake in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Replimune Group during the second quarter worth $583,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.